文献速递眼底病与葡萄膜炎

对Anti-VEGF药物反应良好的黄斑水肿患者每月方案与治疗并延长方案比较:SCORE2随机临床试验次要结局

Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2018-01-01

SCORE2随机临床试验纳入293例视网膜中央静脉或半侧视网膜静脉阻塞相关黄斑水肿且前6个月每月注射反应良好者,随机分为阿柏西普或贝伐珠单抗的每月方案与治疗并延长(TAE)方案。第6至12个月视力字母评分变化组间差异未达统计学显著(阿柏西普1.88,97.5%CI -1.07至4.83,P=0.15;贝伐珠单抗1.98,97.5%CI -1.08至5.03,P=0.15),TAE组注射次数更少,但置信区间宽,作者提醒谨慎解读视力结局相似性。

要点

  • 第6至12个月视力字母评分变化:阿柏西普每月组与TAE组差异1.88(97.5%CI -1.07至4.83,P=0.15),未达统计学显著。
  • 贝伐珠单抗每月组与TAE组视力字母评分变化差异1.98(97.5%CI -1.08至5.03,P=0.15),未达统计学显著。
  • 第6至11个月平均注射次数:阿柏西普每月组5.8次 vs TAE组3.8次(P<0.001);贝伐珠单抗每月组5.8次 vs TAE组4.5次(P<0.001)。

核心结论

  • 第6至12个月,阿柏西普或贝伐珠单抗TAE组注射次数比每月组少1至2次,用于视网膜中央静脉或半侧视网膜静脉阻塞相关黄斑水肿。
  • 因组间差异的置信区间宽,在得出两种方案视力结局相似的结论前需谨慎。

研究设计与样本

  • SCORE2随机临床试验的次要结局分析,纳入美国66家私立诊所或学术中心的293例参与者。
  • 参与者均为视网膜中央静脉阻塞或半侧视网膜静脉阻塞相关黄斑水肿,且在试验前6个月每月注射后达到方案定义的的良好反应。
  • 初始接受每月阿柏西普者随机分为阿柏西普每月方案组(79例)或TAE方案组(80例);初始接受每月贝伐珠单抗者随机分为贝伐珠单抗每月方案组(67例)或TAE方案组(67例)。

主要发现

  • 参与者平均(SD)年龄68.9(11.9)岁,女性127例(43.3%)。
  • 第6至12个月最佳矫正电子视力字母评分变化(每月组减TAE组)的平均治疗组间差异:阿柏西普为1.88(97.5%CI -1.07至4.83;P=0.15),贝伐珠单抗为1.98(97.5%CI -1.08至5.03;P=0.15)。
  • 第6至11个月平均注射次数:阿柏西普每月组5.8次(95%CI 5.6至5.9) vs TAE组3.8次(95%CI 3.5至4.1;P<0.001)。
  • 第6至11个月平均注射次数:贝伐珠单抗每月组5.8次(95%CI 5.6至5.9) vs TAE组4.5次(95%CI 4.2至4.8;P<0.001)。

局限性

  • 组间差异的置信区间宽,在得出两种方案视力结局相似的结论前需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Comparisons of monthly vs treat-and-extend anti-vascular endothelial growth factor (anti-VEGF) regimens for macular edema from central retinal vein occlusion or hemiretinal vein occlusion is needed. OBJECTIVE: To compare visual acuity letter score and central subfield thickness outcomes of participants in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) trial who then received either monthly injections or treat-and-extend (TAE) regimens of aflibercept or bevacizumab after a good response at month 6. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial enrolled participants from 66 private practice or academic centers in the United States. All participants had macular edema associated with central retinal vein occlusion or hemiretinal vein occlusion, had enrolled in the SCORE2 trial, and had a protocol-defined good response to monthly injections in the first 6 months of the trial. Participants initially assigned to receive monthly aflibercept were randomized to aflibercept on a monthly or TAE schedule, and participants initially assigned to receive monthly injections of bevacizumab were randomized to receive bevacizumab on a monthly or TAE schedule. The first participant was randomized in the SCORE2 trial on September 17, 2014, and the last month 12 visit occurred on October 24, 2016. MAIN OUTCOMES AND MEASURES: Change from month 6 to month 12 in best-corrected electronic visual acuity letter score (per the Early Treatment Diabetic Retinopathy Study). RESULTS: The 293 participants had a mean (SD) age of 68.9 (11.9) years; 127 (43.3%) were female. Of these, 79 were randomized to aflibercept on a monthly schedule, 80 to aflibercept on a TAE schedule, 67 to monthly bevacizumab, and 67 to bevacizumab on a TAE schedule. Mean treatment group difference (the change in visual acuity letter score in the monthly group minus the change in the TAE group) from month 6 to month 12 was 1.88 (97.5% CI, -1.07 to 4.83; P = .15) for aflibercept and 1.98 (97.5% CI, -1.08 to 5.03; P = .15) for bevacizumab. In the aflibercept arm, the mean number of injections between months 6 and 11 was 5.8 in the monthly injection group (95% CI, 5.6 to 5.9) and 3.8 in the TAE group (95% CI, 3.5 to 4.1; P < .001); in the bevacizumab arm, the mean number of injections was 5.8 (95% CI, 5.6 to 5.9) in the monthly group and 4.5 in the TAE group (95% CI, 4.2 to 4.8; P < .001). CONCLUSIONS AND RELEVANCE: One to 2 fewer injections of aflibercept or bevacizumab were given to the TAE groups than the monthly groups in months 6 to 12 for macular edema associated with central retinal or hemiretinal vein occlusion. Because of wide confidence intervals on the differences between the groups, caution is warranted before concluding that the regimens are associated with similar vision outcomes. TRIAL REGISTRATION: www.clinicaltrials.gov identifier: NCT01969708.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Scott IU, VanVeldhuisen PC, Ip MS, et al. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. JAMA Ophthalmol. 2018. PMID: 29476687. doi:10.1001/jamaophthalmol.2017.6843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。